^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SJ-C1044

    i
    Other names: SJ-C1044
    Company:
    Samjin Pharma
    Drug class:
    pan-RAF inhibitor, Angiogenesis inhibitor
    Related drugs:
    over1year
    Targeting RAF Isoforms and Tumor Microenvironments in RAS or BRAF Mutant Colorectal Cancers with SJ-C1044 for Anti-Tumor Activity. (PubMed, Curr Issues Mol Biol)
    Thus, SJ-C1044 shows immunomodulatory potential and the ability to enhance antitumor responses. The study underscores the therapeutic potential of SJ-C1044 as a novel pan-RAF inhibitor capable of targeting oncogenic signaling pathways and overcoming immune suppression in CRC.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • KDR (Kinase insert domain receptor) • RAS (Rat Sarcoma Virus) • CSF1R (Colony stimulating factor 1 receptor)
    |
    KRAS mutation • BRAF mutation • RAS mutation
    |
    SJ-C1044